Drug metabolism and personalized therapy最新文献

{"title":"Effect of a polyherbal Unani formulation on left ventricular diastolic dysfunction in hypertensive patients - a randomized single blind placebo controlled clinical trial.","authors":"Asia Khanum, Javed Ali Khan, Arisha Shahid, Mohd Riyazuddin, Mansoor Ahmad Siddiqui","doi":"10.1515/dmpt-2024-0041","DOIUrl":"https://doi.org/10.1515/dmpt-2024-0041","url":null,"abstract":"<p><strong>Objectives: </strong>Diastolic dysfunction represents an important pathophysiological intermediate between hypertension and heart failure. In the last two decades, the prevalence of heart failure patients having normal or near normal ejection fraction (EF) has increased to around 60 %. It thus poses a great morbidity and mortality risk to the population. In view of present scenario of high prevalence, lack of evidence-based therapy, and limited clinical trials, this study aimed to evaluate how a Unani formulation affects the improvement of the left ventricular diastolic function.</p><p><strong>Methods: </strong>This clinical trial was set up as a randomized, placebo-controlled study involving 35 participants, with 18 individuals in the test group and 17 in the control group. Test group received 3.5 g of a polyherbal Unani formulation in capsule form along with 35 mL of an extract of <i>Borago officinalis</i> L. (<i>Arq</i>-<i>e</i>-<i>Gaozaban</i>), divided into two doses after meals. Meanwhile, the control group received a placebo in the same manner over an eight-week period. Follow-ups were conducted every 15 days to assess both subjective and objective parameters in all participants.</p><p><strong>Results: </strong>The test formulation shows significant improvement in dyspnea and diastolic function from baseline to the end of trial (p<0.05), slight improvement in palpitations (p>0.05) and highly significant improvement in easy fatigability (p=0.001) as compared to the control.</p><p><strong>Conclusions: </strong>The present study shows the effectiveness of the test drug in enhancing the diastolic function of left ventricle and alleviating other symptoms associated with ventricular diastolic dysfunction. Nevertheless, additional research with longer follow-up durations is necessary to clarify its efficacy and establish optimal treatment approaches for ventricular diastolic dysfunction in Unani medicine.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141970884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bottom-up PBPK modeling of phenytoin brain disposition in postpartum newborns after intrauterine dosing.","authors":"Mo'tasem M Alsmadi","doi":"10.1515/dmpt-2024-0037","DOIUrl":"https://doi.org/10.1515/dmpt-2024-0037","url":null,"abstract":"<p><strong>Objectives: </strong>The antiepileptic phenytoin has a narrow therapeutic window, nonlinear pharmacokinetics, and can cross the placenta causing apathy and jitteriness in postpartum newborns. Further, the sudden decay of phenytoin concentration can cause withdrawal seizures. This work aimed to assess the brain toxic exposure to phenytoin in newborns after transplacental transfer using neonatal saliva-brain correlations.</p><p><strong>Methods: </strong>The phenytoin dose that the newborn receives transplacentally at birth was estimated using verified physiologically based pharmacokinetic (PBPK) model simulations in third-trimester pregnancy (pregnancy T3). Such doses were used as an input to the newborn PBPK model to estimate the neonatal levels of phenytoin and their correlations in brain extracellular fluid (bECF), plasma, and saliva.</p><p><strong>Results: </strong>The PBPK model-estimated neonatal plasma and bECF concentrations of phenytoin were below the necessary thresholds for anticonvulsant and toxic effects. The neonatal salivary thresholds for phenytoin anticonvulsant and toxic effects were estimated to be 1.3 and 2.5 mg/L, respectively using the plasma-saliva-bECF correlations established herein.</p><p><strong>Conclusions: </strong>The salivary TDM of phenytoin can be a more convenient option for avoiding phenytoin brain toxicity in newborns of epileptic mothers. Still, the appropriateness of using the same adult values of phenytoin anticonvulsant and toxic effects for infants needs investigation.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular pathogenesis of microsatellite instability-high early-stage colorectal adenocarcinoma in India.","authors":"Prasanth Ariyannur, Veena P Menon, Keechilat Pavithran, Roopa R Paulose, Reenu A Joy, Damodaran M Vasudevan","doi":"10.1515/dmpt-2024-0033","DOIUrl":"10.1515/dmpt-2024-0033","url":null,"abstract":"<p><strong>Objectives: </strong>The prevalence of microsatellite instability (MSI) subtype among all colon cancers in India is about 30 %, approximately two times more than that of western population suggesting different molecular pathogeneses.</p><p><strong>Methods: </strong>A <i>NanoString</i> analysis-based Pan cancer differential expression (DE) profile was determined in a primary cohort of early-stage CRC (tumor=10, normal=7), and correlated against MSI status. Using RT-PCR, tumor-specific <i>DE</i> genes were validated in another cohort of MSI-high CRC (n=15).</p><p><strong>Results: </strong>Among the most differentially expressed genes, <i>AXIN2</i>, <i>ETV4,</i> and <i>RNF43</i> were tumor cell-specific signals, while a set of genes including <i>COL11A1</i>, <i>COMP</i>, <i>INHBA</i>, <i>SPP1</i>, <i>MMP3</i>, <i>TLR2</i>, and others were immune cell-specific signals, that had a differential expression between MSI and MSS groups. When overlapped with The Cancer Genome Atlas (TCGA) studies using the Tumor immune estimation resource tool (TIMER), and protein-protein interaction analysis by STRING.db, these genes were segregated to representative tumor cells and immune cells. On validation, the tumor-specific gene signals were inversely associated with <i>TLR4</i> expression.</p><p><strong>Conclusions: </strong>The differential expression distribution of <i>AXIN2</i>, <i>ETV4</i>, and <i>RNF43</i> among tumor and immune cells, suggests more than one pathological subset in the MSI-H subgroup of early-stage CRC in the Indian population.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141751263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The synergy of artificial intelligence and personalized medicine for the enhanced diagnosis, treatment, and prevention of disease.","authors":"Mohammad Abu Zahra, Abdulla Al-Taher, Mohamed Alquhaidan, Tarique Hussain, Izzeldin Ismail, Indah Raya, Mahmoud Kandeel","doi":"10.1515/dmpt-2024-0003","DOIUrl":"10.1515/dmpt-2024-0003","url":null,"abstract":"<p><strong>Introduction: </strong>The completion of the Human Genome Project in 2003 marked the beginning of a transformative era in medicine. This milestone laid the foundation for personalized medicine, an innovative approach that customizes healthcare treatments.</p><p><strong>Content: </strong>Central to the advancement of personalized medicine is the understanding of genetic variations and their impact on drug responses. The integration of artificial intelligence (AI) into drug response trials has been pivotal in this domain. These technologies excel in handling large-scale genomic datasets and patient histories, significantly improving diagnostic accuracy, disease prediction and drug discovery. They are particularly effective in addressing complex diseases such as cancer and genetic disorders. Furthermore, the advent of wearable technology, when combined with AI, propels personalized medicine forward by offering real-time health monitoring, which is crucial for early disease detection and management.</p><p><strong>Summary: </strong>The integration of AI into personalized medicine represents a significant advancement in healthcare, promising more accurate diagnoses, effective treatment plans and innovative drug discoveries.</p><p><strong>Outlook: </strong>As technology continues to evolve, the role of AI in enhancing personalized medicine and transforming the healthcare landscape is expected to grow exponentially. This synergy between AI and healthcare holds great promise for the future, potentially revolutionizing the way healthcare is delivered and experienced.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141598916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Helicobacter pylori</i> eradication therapy for children.","authors":"Kairat Rysbekov, Sagira Abrakhmanova, Rashida Satybaeva, Yekaterina Starosvetova, Almagul Kushugulova","doi":"10.1515/dmpt-2024-0029","DOIUrl":"10.1515/dmpt-2024-0029","url":null,"abstract":"<p><strong>Objectives: </strong>The research aims to investigate the effect of vitamin D supplementation on the efficacy of <i>Helicobacter pylori</i> eradication therapy and to find new drug combinations for the eradication of the bacterium.</p><p><strong>Methods: </strong>A total of 128 children participated in the research. They were distributed under the following criteria: group A were children who tested positive for <i>H. pylori</i> and were treated with the standard so-called triple therapy including vitamin D; group B were children who tested positive for <i>H. pylori</i> and received the standard triple therapy without including vitamin D in the treatment; and group C were children who tested negative for <i>H. pylori</i>. After endoscopic examination, additional venous blood samples were taken from the children to determine vitamin D levels. A controlled study was carried out 45 days after the initial treatment.</p><p><strong>Results: </strong>The overall success rate of eradication therapy was 84.1 %. In group A, the success rate of treatment was 93.5 %, contrary to group B, where the success rate was 75 %. Although there was a difference in the percentage of <i>H. pylori</i> eradication therapy in the main group compared to the control group, there was no significant difference in group B. The success rate of eradication is p=0.082.</p><p><strong>Conclusions: </strong>Following the research results, the addition of vitamin D to the standard triple therapy regimen for <i>H. pylori</i> had no effect. It can therefore be concluded that vitamin D does not significantly increase the efficacy of eradication therapy.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141598894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and pharmacogenetic features of patients with upper gastrointestinal lesions at a multidisciplinary hospital: the role of nonsteroidal anti-inflammatory drugs.","authors":"Natalia P Denisenko, Anna S Zhiryakova, Ivan V Sychev, Alexander V Kryukov, Svetlana N Tuchkova, Olga Y Vakulenko, Oleg V Averkov, Valery I Vechorko, Karin B Mirzaev, Dmitry A Sychev","doi":"10.1515/dmpt-2024-0040","DOIUrl":"10.1515/dmpt-2024-0040","url":null,"abstract":"<p><strong>Objectives: </strong>Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed medications, but their use can be associated with a number of adverse reactions, including upper gastrointestinal lesions. The aim of the study was to identify clinical and pharmacogenetic factors associated with upper gastrointestinal lesions, including those linked to NSAIDs, in patients at a multidisciplinary hospital.</p><p><strong>Methods: </strong>The study included 92 patients (mean age 59.4±16.5 years; 47 women), who underwent esophagogastroduodenoscopy during inpatient treatment. Patients' intake of NSAIDs and gastroprotectors during the year before hospitalization was considered. Demographic, clinical, laboratory data of patients were compared between groups, including genotyping for <i>CYP2C9*2 rs179985</i>, <i>CYP2C9*3 rs1057910</i>, <i>CYP2C8*3 rs11572080</i>, <i>CYP2C8*3 rs10509681</i>, <i>PTGS-1 rs10306135</i>, <i>PTGS-1 rs12353214</i>, and <i>PTGS-2 rs20417</i> using real-time PCR.</p><p><strong>Results: </strong>In NSAIDs⁺ patients, <i>PTGS1</i> rs10306135 AT+TT genotypes increased the chance of developing gastrointestinal complications by 5.4 times (95 % CI=1.30-22.27). In total sample, smoking (OR=3.12, 95 % CI=1.15-8.46), and alcohol intake (OR=4.09, 95 % CI=1.05-15.87) increased odds of gastrointestinal damage. In NSAIDs⁺ patients omeprazole, famotidine and both famotidine and omeprazole during the last year were as ineffective as not taking gastroprotectors; in total sample famotidine (OR=0.19, 95 % CI=0.04-0.93) and two gastroprotectors (OR=0.13, 95 % CI=0.02-0.75) reduced the chance of upper gastrointestinal lesions.</p><p><strong>Conclusions: </strong>Pharmacogenetic features of patients may significantly contribute to the development NSAIDs-induced upper gastrointestinal injuries.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141598915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of <i>ABCB1</i>, <i>CYP3A4</i> and <i>CYP3A5</i> gene polymorphisms on apixaban trough concentration and bleeding risk in patients with atrial fibrillation.","authors":"Alena I Skripka, Pavel M Krupenin, Olga N Kozhanova, Anna A Kudryavtseva, Ludmila V Fedina, Kristina A Akmalova, Pavel O Bochkov, Anastasiya A Sokolova, Dmitriy A Napalkov, Dmitriy A Sychev","doi":"10.1515/dmpt-2024-0013","DOIUrl":"10.1515/dmpt-2024-0013","url":null,"abstract":"<p><strong>Objectives: </strong>Apixaban, a direct oral anticoagulant, is increasingly used worldwide for the treatment and prevention of venous thromboembolism and ischemic stroke in patients with nonvalvular atrial fibrillation (AF). Obviously, one of the ways to enhance effectiveness and safety of drug therapy is a personalized approach to therapy, which involves pharmacogenetic and pharmacokinetic tests. The study aims to investigate the effect of <i>CYP3A4*22</i>, <i>CYP3A5*3</i> and <i>ABCB1</i> polymorphisms on the pharmacokinetics of apixaban and the risk of bleeding.</p><p><strong>Methods: </strong>A total of 84 patients were enrolled in this prospective observational study. All patients received apixaban 5 or 2.5 mg twice daily. Real-time polymerase chain reaction was used to evaluate single-nucleotide polymorphisms of the <i>ABCB1</i> gene (rs1045642 and rs4148738), <i>CYP3A4*22</i> (rs35599367) C>T, <i>CYP3A5*3</i> (rs776746) A>G. A plasma trough concentration/dose (C/D) ratio was used as a pharmacokinetic index.</p><p><strong>Results: </strong>The C/D ratio was higher in patients aged >80 years (F(1)=11.209, p=0.00124) and was affected by serum creatinine (>133 μmol/L, F(1)=6.7, p=0.01124). <i>ABCB1</i> (rs1045642 and rs4148738), <i>CYP3A5</i> (<i>rs776746</i>) and <i>CYP3A4</i> (rs35599367) polymorphisms did not show a correlation with C/D ratio of apixaban. Multivariate logistic regression analyses showed that none of the clinical or genetic factors predicted the fact of bleeding.</p><p><strong>Conclusions: </strong>We report no significant association between <i>ABCB1</i> gene polymorphisms (rs1045642 and rs4148738), <i>CYP3A4*22</i> (rs35599367) C>T, <i>CYP3A5*3</i> (rs776746) A>G and bleeding events on apixaban treatment. Complementing the existing criteria with pharmacogenetic and pharmacokinetics information for the patients with AF will enable further individualization of apixaban.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141466880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of tumor necrosis factor-<i>α rs1800629</i> and interleukin-<i>10 rs1800872</i> genetic variants on type 2 diabetes mellitus susceptibility and metabolic parameters among Jordanians.","authors":"Lana Nasrallah Mousa, Yazun Jarrar, Munir Gharaibeh, Hussam Alhawari","doi":"10.1515/dmpt-2024-0002","DOIUrl":"10.1515/dmpt-2024-0002","url":null,"abstract":"<p><strong>Objectives: </strong>Diabetes mellitus (DM) is a complex chronic illness with diverse pathogenesis and associations with health complications. Genetic factors significantly contribute to DM development, and tumor necrosis factor alpha (<i>TNF-α</i>) and interleukin-10 (<i>IL-10</i>) genes play major roles. This study aims to explore the influence of <i>TNF-α rs1800629</i> and <i>IL-10 rs1800872</i> genetic variants on T2DM development in Jordanian patients at Jordan University Hospital.</p><p><strong>Methods: </strong>One-hundred and 60 diabetic and 159 non-diabetic subjects were genotyped for <i>TNF-α rs1800629</i>. Additionally, 181 diabetic and 191 non-diabetic subjects were genotyped for <i>IL-10 rs1800872</i> using PCR-RFLP genotyping method. The demographic, lipid, and glycemic parameters of the patients were obtained from the computer records in the hospital.</p><p><strong>Results: </strong><i>TNF-α rs1800629</i> and <i>IL-10 rs1800872</i> genetic variants exhibited significant different frequencies in non-T2DM subjects and T2DM patients. The difference in <i>TNF-α rs1800629</i> genotype frequency between non-T2DM and T2DM participants was significant under the dominant model, while the <i>IL-10 rs1800872</i> genotype frequency was significant under the recessive model. A significant association (p<0.05) was observed between <i>TNF-α rs1800629</i> and total cholesterol levels, and between <i>IL-10 rs1800872</i> polymorphism and glycosylated hemoglobin (HbA_1c) and creatinine levels among T2DM patients.</p><p><strong>Conclusions: </strong><i>TNF-α rs1800629</i> and <i>IL-10 rs1800872</i> are identified as genetic risk factors for T2DM. These variants also correlate with variations in cholesterol, HbA_1c, and creatinine levels among T2DM patients. Larger clinical studies are warranted to validate these findings.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140916226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CYP2D6 inhibition by diphenhydramine leading to fatal hydrocodone overdose.","authors":"Aaron G Whitt, Saeed A Jortani","doi":"10.1515/dmpt-2023-0081","DOIUrl":"10.1515/dmpt-2023-0081","url":null,"abstract":"<p><strong>Objectives: </strong>Fatal drug overdoses often involve multiple co-intoxicants, including opioids. Hydrocodone, the most prescribed opioid for pain management, is metabolized to the active metabolite hydromorphone by hepatic CYP2D6. Inhibition of CYP2D6 by other compounds can disrupt the analgesic properties of hydrocodone and extend its half-life. Diphenhydramine is an over-the-counter cold medication and is known to inhibit CYP2D6 activity.</p><p><strong>Case presentation: </strong>A woman in her late 50s was prescribed hydrocodone/acetaminophen (Norco^® 10/325). Days before her death, she began taking diphenhydramine for cold symptoms. A post-mortem toxicology report detected the following compounds by High Performance Liquid Chromatography/Time of Flight-Mass Spectrometry (LC/TOF-MS) analysis: acetaminophen (14 μg/mL), hydrocodone (410 ng/mL), dihydrocodeine (24 ng/mL), and diphenhydramine (150 ng/mL). Hydromorphone was not detected (<2 ng/mL). All compounds were detected in therapeutic concentrations, except for hydrocodone, which was present at lethal concentrations.</p><p><strong>Conclusions: </strong>This case highlights a fatal drug-drug interaction between hydrocodone and diphenhydramine. The estimated total body burden of hydrocodone was 6- to 12-fold higher than acetaminophen, which is unexpected, as these two drugs were administered as a single formulation and have similar half-lives. Furthermore, hydromorphone was undetectable. Taken together, these findings are highly suggestive of a fatal opioid overdose precipitated by diphenhydramine.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140916204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of <i>ABCB1</i> genetic polymorphism on carbamazepine dose requirement among Southern Indian persons with epilepsy.","authors":"Elango Dhivya, Ramasamy Kesavan, Nair P Pradeep","doi":"10.1515/dmpt-2023-0054","DOIUrl":"10.1515/dmpt-2023-0054","url":null,"abstract":"<p><strong>Objectives: </strong>Carbamazepine (CBZ) is one of the oldest, yet first line drugs for treating epilepsy. However, there is a large inter-individual difference in requirement of maintenance dose and one third of persons treated with antiepileptic drugs (AEDs) exhibit drug resistance to therapy. One of the proposed mechanisms for the drug resistance was increased expression of efflux transporter P-glycoprotein. The pharmacogenetic studies of drug transporters (<i>ABCB1</i>) done in combination therapies of AEDs were inconclusive. Hence, we have attempted to study the impact of <i>ABCB1 3435C>T</i> genetic polymorphism and CBZ monotherapy in persons with epilepsy (PWE) from South India, which is a genetically distinct population<b>.</b> With this background, this study was aimed to determine the dose of CBZ in <i>ABCB1 3435C>T</i> genotypes and to determine the distribution of <i>ABCB1 3435C>T</i> genotypes (which codes P-glycoprotein) between responders and non-responders to CBZ therapy.</p><p><strong>Methods: </strong>A cross sectional study was conducted in 200 persons with epilepsy, who were categorised as responders and non-responders according to ILAE (international league against epilepsy) criteria. Eligible participants were enrolled from the epilepsy clinic of the neurology department and five ml of blood was collected. DNA extraction and genotyping were done by phenol-chloroform method and real time polymerase chain reaction (RT-PCR), respectively.</p><p><strong>Results: </strong>The mean maintenance dose of carbamazepine was statistically significant among different genotypes (p<0.05) of <i>ABCB1 3435C>T</i> (526 vs. 637 mg/day in CC vs. TT genotype). There was no significant association between <i>ABCB1 3435C>T</i> polymorphism (p=0.827) and CBZ resistance in PWE. Duration of disease and age of onset were found to be significant in predicting the response to CBZ therapy.</p><p><strong>Conclusions: </strong>We report that <i>ABCB1 3435C>T</i> polymorphism is significantly associated with an increase in dose requirement of CBZ in persons with epilepsy from South India.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140174080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}